Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

130 ARTÍCULOS , VIENDO DEL 16 AL 30

Rapidly progressive Alzheimer's disease: a multicenter update

Schmidt C, Haïk S, Satoh K, Rábano A, Martinez-Martin P, Roeber S, Brandel JP, Calero-Lara M, de Pedro-Cuesta J, Laplanche JL, Hauw JJ, Kretzschmar H, Zerr I.

J Alzheimers Dis. 2012;30(4):751-6. doi: 10.3233/JAD-2012-120007.

Relevance of in vivo neurophysiological biomarkers for mild cognitive impairment and Alzheimer's disease

Yamasaki T, Horie S, Muranaka H, Kaseda Y, Mimori Y, Tobimatsu S.

J Alzheimers Dis. 2012;31 Suppl 3:S137-54. doi: 10.3233/JAD-2012-112093.

Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients

Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G.

J Alzheimers Dis. 2012;30(4):745-9. doi: 10.3233/JAD-2012-112123.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10. doi: 10.1001/archneurol.2012.90.

Brain imaging in Alzheimer disease

Johnson KA, Fox NC, Sperling RA, Klunk WE.

Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi: 10.1101/cshperspect.a006213.

Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies

Ventriglia M, Bucossi S, Panetta V, Squitti R.

J Alzheimers Dis. 2012;30(4):981-4. doi: 10.3233/JAD-2012-120244.

Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms

Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M.

Arch Neurol. 2012 Aug;69(8):1018-25. doi: 10.1001/archneurol.2012.26.

Investigating missing data in Alzheimer disease studies

Schott JM, Bartlett JW.

Neurology. 2012 May 1;78(18):1370-1. doi: 10.1212/WNL.0b013e318253d66b. Epub 2012 Apr 4.

Recruitment methods for United States Alzheimer disease prevention trials

Schneider LS.

J Nutr Health Aging. 2012 Apr;16(4):331-5. doi: 10.1007/s12603-012-0011-6.

Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA

Regeniter A, Kuhle J, Baumann T, Sollberger M, Herdener M, Kunze U, Camuso MC, Monsch AU.

Methods. 2012 Apr;56(4):494-9. doi: 10.1016/j.ymeth.2012.03.019. Epub 2012 Apr 6.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6.

Does Alzheimer's disease with early onset progress faster than with late onset? A case-control study of clinical progression and cerebrospinal fluid biomarkers

Grønning H, Rahmani A, Gyllenborg J, Dessau RB, Høgh P.

Dement Geriatr Cogn Disord. 2012;33(2-3):111-7. doi: 10.1159/000337386. Epub 2012 Apr 12.

Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play

Jack CR Jr.

Radiology. 2012 May;263(2):344-61. doi: 10.1148/radiol.12110433.

Cerebrospinal fluid biomarkers in Alzheimer's disease and geriatric depression: preliminary findings from Brazil

Reis T, Brandão CO, Freire Coutinho ES, Engelhardt E, Laks J.

CNS Neurosci Ther. 2012 Jul;18(7):524-9. doi: 10.1111/j.1755-5949.2012.00311.x. Epub 2012 Apr 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias